ESMO Congress | Conference

Atezolizumab Plus Chemo Significantly Improves pCR Rates in Early TNBC, Irrespective of PD-L1 Status

September 20th 2020

The addition of neoadjuvant atezolizumab to nab-paclitaxel plus doxorubicin and cyclophosphamide significantly improved pathologic complete responses in patients with stage 2 or stage 3 triple-negative breast cancer, compared with placebo plus chemotherapy.

HAIC Shows Better Efficacy and Safety in Unresectable HCC Versus Standard of Care

September 20th 2020

Overall survival was significantly improved in patients who received hepatic arterial infusion chemotherapy with oxaliplatin, fluorouracil, and leucovorin compared with transarterial chemoembolization.

Dr. Zalcberg on Updated Results from the Phase 3 INVICTUS Study in Advanced GIST

September 20th 2020

John Zalcberg, PhD, OAM, discusses updated results from the phase 3 INVICTUS trial in advanced gastrointestinal stromal tumor.

Dr. Solomon on the Results of the Phase 3 CROWN Study in ALK-Positive NSCLC

September 20th 2020

Benjamin Solomon, MBBS, PhD, FRACP, discusses interim findings from the phase 3 CROWN study in ALK-positive non–small cell lung cancer.

Frontline Lorlatinib Bests Crizotinib in Advanced ALK+ NSCLC

September 20th 2020

First-line treatment with the third-generation ALK TKI lorlatinib significantly improved progression-free survival, and also was associated with higher overall and intracranial response rates, compared with crizotinib in patients with ALK-positive non–small cell lung cancer.

Abemaciclib/Tamoxifen Shows OS Benefit in HR+, HER2- Metastatic Breast Cancer

September 20th 2020

The addition of tamoxifen to abemaciclib resulted in an improvement in overall survival compared with abemaciclib monotherapy in in patients with hormone receptor–positive, HER2-negative metastatic breast cancer, with benefit observed across all patient subgroups.

Dostarlimab Demonstrates Durable Antitumor Activity in Mismatch Repair Proficient/dMMR Endometrial Cancer

September 20th 2020

Dostarlimab showcased durable antitumor activity in patients with advanced or recurrent DNA mismatch repair deficient and proficient endometrial cancer, with a notable disease control rate and a promising safety profile.

Sacituzumab Govitecan Significantly Improves Survival in Metastatic TNBC

September 19th 2020

Treatment with sacituzumab govitecan led to a 59% reduction in the risk of disease progression or death compared with physician’s choice of single-agent chemotherapy in patients with previously treated metastatic triple-negative breast cancer.

Sacituzumab Govitecan Shows Sustained Activity in Heavily Pretreated Metastatic Urothelial Carcinoma

September 19th 2020

Sacituzumab govitecan-hziy continued to showcase significant activity with favorable tolerability in heavily pretreated patients with metastatic urothelial carcinoma who progressed on both platinum-based chemotherapy and checkpoint inhibition.

Spartalizumab/Dabrafenib Misses PFS End Point in Melanoma

September 19th 2020

Spartalizumab plus dabrafenib did not significantly improve progression-free survival over dabrafenib/trametinib in patients with untreated BRAF V600-mutant unresectable or metastatic melanoma.

Updated Data Demonstrate Continued PFS and OS Benefit With Ripretinib in Advanced GIST

September 19th 2020

The novel broad-spectrum KIT and PDGFRα inhibitor ripretinib continued to demonstrate clinically meaningful benefit as a fourth- or later-line treatment for patients with advanced gastrointestinal stromal tumors.

Higher PFS Rate Reported for Encorafenib/Binimetinib Combo Followed by Immunotherapy in Metastatic Melanoma

September 19th 2020

Early findings from a phase II efficacy and safety study may be the first step in developing a definitive rationale for sequencing targeted therapies and immunotherapies in patients with metastatic melanoma.

Urothelial Cancer Treatment Combination Fails To Meet OS End Points

September 19th 2020

Neither monotherapy with durvalumab or combination treatment with durvalumab plus tremelimumab met co-primary end points of overall survival vs chemotherapy for the treatment of metastatic urothelial cancer.

First-Line Pembrolizumab Improves Health-Related Quality of Life in DNA Repair-Deficient Metastatic Colorectal Cancer

September 19th 2020

As first-line therapy for patients with microsatellite instability-high and/or mismatch-repair deficient metastatic colorectal cancer, pembrolizumab improves quality of life compared with standard chemotherapy.

Nivolumab/Ipilimumab Combo Shows Durable Benefit at 4 Years in Advanced RCC

September 19th 2020

The benefits conferred by the combination of nivolumab and ipilimumab for the first-line treatment of advanced renal cell carcinoma remained durable after 4-year follow-up compared with treatment with sunitinib.

More Frequent Dosing of Lanreotide Autogel Delays the Use of More Toxic Treatments in Pancreatic, Midgut NETs

September 19th 2020

Improvements in disease-free survival and progression-free survival were observed in patients with progressive pancreatic or midgut neuroendocrine tumors whose frequency of dosing for lanreotide Autogel was increased from 120 mg every 28 days to every 14 days.

First-in-Human Study of RO7122290 Shows Promise in Patients With Select Solid Tumors

September 19th 2020

Safety and preliminary antitumor activity with the bispecific antibody RO7122290 alone or in combination with atezolizumab demonstrated preliminary antitumor activity and was safe for the treatment of patients with advanced solid tumors.

Balstilimab Monotherapy or Plus Zalifrelimab Active in Recurrent/Metastatic Cervical Cancer

September 19th 2020

The investigative PD-1 inhibitor balstilimab as a single agent and combined with the CTLA-4 inhibitor zalifrelimab showed promising objective response rates, regardless of PD-L1 expression, and a tolerable safety profile in patients with recurrent/metastatic cervical cancer.

PD-L1 Status Guides TIL activity in NeoTRIPaPDL1

September 19th 2020

Although atezolizumab did not improve pathological complete response when added to carboplatin and nab-paclitaxel, the immunotherapy increased the pCR by 10% or more in “immune-rich” groups with high-risk and locally advanced triple-negative breast cancer, and also turned PD-L1 negative tumors positive in most immunotherapy-treated patients.

Nivolumab/Cabozantinib Combo Doubles PFS in Frontline RCC

September 19th 2020

The combination of nivolumab and cabozantinib led to a 49% reduction in the risk of disease progression or death, while also significantly improving overall survival and doubling objective response rate, compared with sunitinib in the first-line treatment of patients with advanced renal cell carcinoma.